498 related articles for article (PubMed ID: 26432476)
1. Subcutaneous Ustekinumab Provides Clinical Benefit for Two-Thirds of Patients With Crohn's Disease Refractory to Anti-Tumor Necrosis Factor Agents.
Wils P; Bouhnik Y; Michetti P; Flourie B; Brixi H; Bourrier A; Allez M; Duclos B; Grimaud JC; Buisson A; Amiot A; Fumery M; Roblin X; Peyrin-Biroulet L; Filippi J; Bouguen G; Abitbol V; Coffin B; Simon M; Laharie D; Pariente B;
Clin Gastroenterol Hepatol; 2016 Feb; 14(2):242-50.e1-2. PubMed ID: 26432476
[TBL] [Abstract][Full Text] [Related]
2. Ustekinumab for the Treatment of Refractory Crohn's Disease: The Spanish Experience in a Large Multicentre Open-label Cohort.
Khorrami S; Ginard D; Marín-Jiménez I; Chaparro M; Sierra M; Aguas M; Sicilia B; García-Sánchez V; Suarez C; Villoria A; Taxonera C; Velasco-Guardado A; Martínez-González J; Gisbert JP
Inflamm Bowel Dis; 2016 Jul; 22(7):1662-9. PubMed ID: 27306072
[TBL] [Abstract][Full Text] [Related]
3. Comparative Effectiveness of Ustekinumab and Anti-TNF Agent as First-Line Biological Therapy in Luminal Crohn's Disease: A Retrospective Study From 2 Referral Centers.
Rivière P; Kanters C; Pellet G; Ni A; Hupé M; Aboulhamid N; Poullenot F; Bitton A; Zerbib F; Lakatos PL; Afif W; Laharie D; Bessissow T
Inflamm Bowel Dis; 2023 Jun; 29(6):923-931. PubMed ID: 35917111
[TBL] [Abstract][Full Text] [Related]
4. Long-term efficacy and safety of ustekinumab in 122 refractory Crohn's disease patients: a multicentre experience.
Wils P; Bouhnik Y; Michetti P; Flourie B; Brixi H; Bourrier A; Allez M; Duclos B; Serrero M; Buisson A; Amiot A; Fumery M; Roblin X; Peyrin-Biroulet L; Filippi J; Bouguen G; Abitbol V; Coffin B; Simon M; Laharie D; Pariente B;
Aliment Pharmacol Ther; 2018 Mar; 47(5):588-595. PubMed ID: 29315694
[TBL] [Abstract][Full Text] [Related]
5. Association Between Ustekinumab Trough Concentrations and Clinical, Biomarker, and Endoscopic Outcomes in Patients With Crohn's Disease.
Battat R; Kopylov U; Bessissow T; Bitton A; Cohen A; Jain A; Martel M; Seidman E; Afif W
Clin Gastroenterol Hepatol; 2017 Sep; 15(9):1427-1434.e2. PubMed ID: 28365485
[TBL] [Abstract][Full Text] [Related]
6. Anti-TNF therapy for genital fistulas in female patients with Crohn's disease: a nationwide study from the Groupe d'Etude Thérapeutique des Affections Inflammatoires du tube Digestif (GETAID).
Le Baut G; Peyrin-Biroulet L; Bouguen G; Gornet JM; Stefanescu C; Amiot A; Laharie D; Altwegg R; Fumery M; Trang C; Vuitton L; Simon M; Gilletta de Saint Joseph C; Nahon S; Caillo L; Del Tedesco E; Plastaras L; Aubourg A; Pineton de Chambrun G; Seksik P; Viennot S
Aliment Pharmacol Ther; 2018 Oct; 48(8):831-838. PubMed ID: 30194687
[TBL] [Abstract][Full Text] [Related]
7. Long-term outcome of enterocutaneous fistula in patients with Crohn's disease treated with anti-TNF therapy: a cohort study from the GETAID.
Amiot A; Setakhr V; Seksik P; Allez M; Treton X; De Vos M; Laharie D; Colombel JF; Abitbol V; Reimund JM; Moreau J; Veyrac M; Flourié B; Cosnes J; Lemann M; Bouhnik Y
Am J Gastroenterol; 2014 Sep; 109(9):1443-9. PubMed ID: 25091063
[TBL] [Abstract][Full Text] [Related]
8. Clinical, endoscopic and radiographic outcomes with ustekinumab in medically-refractory Crohn's disease: real world experience from a multicentre cohort.
Ma C; Fedorak RN; Kaplan GG; Dieleman LA; Devlin SM; Stern N; Kroeker KI; Seow CH; Leung Y; Novak KL; Halloran BP; Huang VW; Wong K; Blustein PK; Ghosh S; Panaccione R
Aliment Pharmacol Ther; 2017 May; 45(9):1232-1243. PubMed ID: 28252210
[TBL] [Abstract][Full Text] [Related]
9. Ustekinumab: "Real-world" outcomes and potential predictors of nonresponse in treatment-refractory Crohn's disease.
Hoffmann P; Krisam J; Wehling C; Kloeters-Plachky P; Leopold Y; Belling N; Gauss A
World J Gastroenterol; 2019 Aug; 25(31):4481-4492. PubMed ID: 31496626
[TBL] [Abstract][Full Text] [Related]
10. Ustekinumab for Crohn's Disease: Results of the ICC Registry, a Nationwide Prospective Observational Cohort Study.
Biemans VBC; van der Meulen-de Jong AE; van der Woude CJ; Löwenberg M; Dijkstra G; Oldenburg B; de Boer NKH; van der Marel S; Bodelier AGL; Jansen JM; Haans JJL; Theeuwen R; de Jong D; Pierik MJ; Hoentjen F
J Crohns Colitis; 2020 Jan; 14(1):33-45. PubMed ID: 31219157
[TBL] [Abstract][Full Text] [Related]
11. Comparative effectiveness of ustekinumab or vedolizumab after one year in 130 patients with anti-TNF-refractory Crohn's disease.
Townsend T; Razanskaite V; Dodd S; Storey D; Michail S; Morgan J; Davies M; Penman D; Watters C; Swaminathan M; Sabine J; Chapman A; Smith PJ; Flanagan PK; Reilly I; Bodger K; Subramanian S
Aliment Pharmacol Ther; 2020 Oct; 52(8):1341-1352. PubMed ID: 32955122
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of ustekinumab in the induction therapy of TNF-α-refractory Crohn's disease patients: a systematic review and meta-analysis.
Kawalec P; Moćko P; Malinowska-Lipien I; Brzostek T
J Comp Eff Res; 2017 Oct; 6(7):601-612. PubMed ID: 28660802
[TBL] [Abstract][Full Text] [Related]
13. Subcutaneous ustekinumab for the treatment of anti-TNF resistant Crohn's disease--the McGill experience.
Kopylov U; Afif W; Cohen A; Bitton A; Wild G; Bessissow T; Wyse J; Al-Taweel T; Szilagyi A; Seidman E
J Crohns Colitis; 2014 Nov; 8(11):1516-22. PubMed ID: 24996483
[TBL] [Abstract][Full Text] [Related]
14. Positioning Ustekinumab in Crohn's Disease: From Clinical Evidence to Clinical Practice.
Danese S; Bonovas S; Peyrin-Biroulet L
J Crohns Colitis; 2017 Oct; 11(10):1258-1266. PubMed ID: 28575273
[TBL] [Abstract][Full Text] [Related]
15. Ustekinumab: A Review in Moderate to Severe Crohn's Disease.
Lamb YN; Duggan ST
Drugs; 2017 Jul; 77(10):1105-1114. PubMed ID: 28528528
[TBL] [Abstract][Full Text] [Related]
16. Long-term Maintenance of Clinical, Endoscopic, and Radiographic Response to Ustekinumab in Moderate-to-Severe Crohn's Disease: Real-world Experience from a Multicenter Cohort Study.
Ma C; Fedorak RN; Kaplan GG; Dieleman LA; Devlin SM; Stern N; Kroeker KI; Seow CH; Leung Y; Novak KL; Halloran BP; Huang VW; Wong K; Blustein PK; Ghosh S; Panaccione R
Inflamm Bowel Dis; 2017 May; 23(5):833-839. PubMed ID: 28328624
[TBL] [Abstract][Full Text] [Related]
17. Concomitant use of an immunomodulator with ustekinumab as an induction therapy for Crohn's disease: A systematic review and meta-analysis.
Yoshihara T; Shinzaki S; Amano T; Iijima H; Takehara T; Inoue N; Uchino M; Esaki M; Kobayashi T; Saruta M; Sugimoto K; Nakamura S; Hata K; Hirai F; Hiraoka S; Fujii T; Matsuura M; Matsuoka K; Watanabe K; Nakase H; Watanabe M
J Gastroenterol Hepatol; 2021 Jul; 36(7):1744-1753. PubMed ID: 33450096
[TBL] [Abstract][Full Text] [Related]
18. The effectiveness of either ustekinumab or vedolizumab in 239 patients with Crohn's disease refractory to anti-tumour necrosis factor.
Alric H; Amiot A; Kirchgesner J; Tréton X; Allez M; Bouhnik Y; Beaugerie L; Carbonnel F; Meyer A
Aliment Pharmacol Ther; 2020 May; 51(10):948-957. PubMed ID: 32249966
[TBL] [Abstract][Full Text] [Related]
19. Ustekinumab to treat Crohn's disease.
Gisbert JP; Chaparro M
Gastroenterol Hepatol; 2017 Dec; 40(10):688-698. PubMed ID: 29042094
[TBL] [Abstract][Full Text] [Related]
20. Ustekinumab and Anti-Interleukin-23 Agents in Crohn's Disease.
Deepak P; Sandborn WJ
Gastroenterol Clin North Am; 2017 Sep; 46(3):603-626. PubMed ID: 28838418
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
